Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
Group three received NAC, and Group four received MET + NAC
Studies have shown their positive impact on kidney outcomes in patients with T2D compared to placebo
This medically supervised weight management medication helps you achieve a steady, healthy weight while boosting your confidence and long-term wellness for a transformative journey like no other
Promotes neuroplasticity, memory and cognitive function by activating the HGF/c-Met receptor
PMID: 39444151
